Report of Foreign Issuer (6-k)
27 February 2018 - 8:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2018
Commission File Number
001-36866
SUMMIT THERAPEUTICS PLC
(Translation of registrants name into English)
136a Eastern
Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F:
FORM
20-F ☒ FORM
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934:
YES ☐ NO ☒
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b):
On February 26, 2018, Summit Therapeutics plc issued a press release announcing further findings from the
24-week
interim data from its Phase 2 clinical trial of ezutromid for the treatment of Duchenne muscular dystrophy, which is also referred to as PhaseOut DMD. The related press release is attached hereto as Exhibit
99.1.
The information in this Report on Form
6-K,
including Exhibit 99.1, shall not be deemed filed
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
SUMMIT THERAPEUTICS PLC
|
|
|
By:
|
|
/s/ Erik Ostrowski
|
|
|
Erik Ostrowski
|
|
|
Chief Financial Officer
|
Date: February 26, 2018
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press Release dated February 26, 2018
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024